Assessing Whether Henry Schein (HSIC) Shares Look Undervalued After Recent Weak Momentum

Recent share performance and business snapshot

Henry Schein (HSIC) has drawn investor attention after a period of weaker share performance, with the stock showing negative returns over the past week, month, and past 3 months, despite a modest positive 1 year total return.

The company provides a broad range of health care products and services, with revenue of US$13.2b and net income of US$398.0m, primarily through its Global Distribution and Value Added Services segment.

See our latest analysis for Henry Schein.

At a share price of US$72.29, Henry Schein’s short term share price returns have been weak, yet the 1 year total shareholder return of 2.16% shows only modest progress. This suggests that momentum has been fading rather than building recently.

If this softer momentum has you looking beyond Henry Schein, it could be a good moment to scan the broader market using a focused list of healthcare technology names and compare them with 36 healthcare AI stocks

So with Henry Schein’s shares soft in the short term but still generating a 1 year total return and trading below some valuation estimates, are you looking at a genuine opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 19.5% Undervalued

Henry Schein’s most followed valuation narrative puts fair value at $89.79 versus the current $72.29 share price, framing a material discount and a detailed set of expectations behind it.

The company is experiencing strong growth in high-margin businesses such as Specialty Products, Technology, and private-label offerings, and expects over 50% of non-GAAP operating income to come from these segments, supporting structurally higher gross margins and likely driving earnings expansion. Investments in digital workflow, AI solutions, and integrated cloud-based practice management platforms are accelerating recurring SaaS revenues and client retention, positioning Henry Schein to benefit from the ongoing digital transformation of healthcare, which should support both revenue growth and improved margins.

Read the complete narrative.

For readers interested in what earnings path and margin mix would need to align to support that valuation gap, and how much multiple compression is already reflected in the current pricing, the full narrative provides those details.

Result: Fair Value of $89.79 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this upside view could be challenged if competitive pricing continues to pressure distribution margins, or if dental patient traffic and staffing shortages restrict underlying volume growth.

Find out about the key risks to this Henry Schein narrative.

Next Steps

With mixed signals on value and business momentum, it is worth looking beyond the headline numbers and weighing both the concerns and the upside yourself. To see the full picture of what investors are worried about and what they are excited about, start with these 4 key rewards and 2 important warning signs

Looking for more investment ideas?

If you are weighing up Henry Schein today, it makes sense to broaden your watchlist and compare it with other clear, data driven ideas across the market.

• Spot opportunities that combine quality and attractive pricing by scanning 54 high quality undervalued stocks and see which names stand out against your return and risk expectations.
• Prioritise resilience by focusing on companies that pass balance sheet checks with the solid balance sheet and fundamentals stocks screener (39 results) so you are not relying only on headline earnings.
• Get ahead of the crowd by reviewing the screener containing 26 high quality undiscovered gems before these names attract wider attention and potential re ratings.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com